hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06357949 id: E2-23-3615 briefTitle: The Effectiveness of High-intensity Laser Therapy on Plantar Flexor Muscle Spasticity in Stroke Patients overallStatus: RECRUITING date: 2024-04-05 date: 2024-09 date: 2024-09 date: 2024-04-10 date: 2024-04-29 name: Hitit University class: OTHER briefSummary: The aim of this study is to investigate the effectiveness of high-intensity laser therapy for treating plantar flexor muscle spasticity in subacute and chronic stroke patients, focusing on its impact on spasticity, joint range of motion, pain, muscle thickness, functional ambulation, and quality of life. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 20 type: ESTIMATED name: High-intensity laser name: Sham laser measure: 10-Meter Walk Test measure: Visual analogue scale for pain (VAS- pain) measure: Modified Ashworth Scale measure: Joint Range of Motion (ROM) Measurement measure: Ultrasonography measure: Timed Up and Go test measure: Stroke Specific Quality of Life Scale sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara Gaziler Physical Therapy and Rehabilitation Training and Research Hospital status: RECRUITING city: Ankara country: Turkey name: Tuğba Atan role: CONTACT phone: +90 312 2911000 phoneExt: 1414 email: tubaatan@gmail.com lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06357936 id: CNMT002 briefTitle: Nanofat Grafting as a Method of Treating Critical Limb Ischemia overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2024-11-20 date: 2025-02-20 date: 2024-04-10 date: 2024-04-10 name: Center of New Medical Technologies class: OTHER briefSummary: This clinical trial will investigate nano fat grafting as a method for treating critical limb ischemia. The method involves the collection of adipose tissue under tumescent anesthesia through a separate incision in the anterior abdominal wall, followed by preparation and injection of nano fat into the tissues of the foot and leg without additional drug therapy. The novelty of this method lies in the use of autologous stem cells and growth factors, differing from current treatments like neovasculgen, which is a plasmid DNA-based treatment. The trial aims to assess the safety and effectiveness of nano fat grafting, including pain relief, the frequency of intraoperative complications, increased distance of pain-free walking, limb preservation, and mortality rates.
Statistical methods will involve quantitative data presented as mean ± standard deviation, with qualitative traits compared using the Chi-square test or Fisher's exact test. The planned patient number is 40, aiming to demonstrate the effectiveness and safety of nano fat grafting for critical limb ischemia treatment compared to current treatments. conditions: Limb Ischemia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: nano-fat grafting in chronic limb ischaemia name: sham comparator measure: Percent of pain absence in experimental group measure: Number of any intraoperative complications measure: Number of any inhospital complications measure: Number of saved limbs measure: Percent change in visual analog pain score (VAS) change sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Center of New Medical Technologies city: Novosibirsk state: Novosibirsk Region zip: 630090 country: Russian Federation name: Andrey V Ponomarenko, MD role: CONTACT lat: 55.0415 lon: 82.9346 hasResults: False
nctId: NCT06357923 id: 23-PP-13 id: 2024-A00321-46 type: OTHER domain: ANSM briefTitle: Study of the Evolution of the Expression of the LAMP-2 Protein During the Advance in Age overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-05-02 date: 2026-05-01 date: 2024-04-10 date: 2024-04-10 name: Centre Hospitalier Universitaire de Nice class: OTHER briefSummary: Recruitment on the RAV pole in consultation or day hospital. Competitive recruitment of subjects \> 60 years of age respecting a male/female ratio = 1. conditions: Aging studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 100 type: ESTIMATED name: dosage measure: Expression level of LAMP2 (protein and isoform A and B mRNA) measure: Presence of mutation in the "Oncomin Myeloid Reasearch Assay" gene panel targeting approximately 40 Different genes sex: ALL minimumAge: 60 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chu de Nice city: Nice zip: 06003 country: France name: Andrea CICCONE role: CONTACT phone: 0492034702 email: ciccone.a@hu-nice.fr name: marion causeret role: CONTACT phone: 0492034702 email: causeret.m@chu-nice.fr name: Andrea CICCONE role: PRINCIPAL_INVESTIGATOR lat: 43.70313 lon: 7.26608 hasResults: False
nctId: NCT06357910 id: HM-EMMA-102 briefTitle: A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions overallStatus: NOT_YET_RECRUITING date: 2024-05-17 date: 2024-06-29 date: 2024-06-29 date: 2024-04-10 date: 2024-04-12 name: Hanmi Pharmaceutical Company Limited class: INDUSTRY briefSummary: The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HCP2303 and co-administration of each component in fed condition in healthy volunteers. conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 34 type: ESTIMATED name: HCP2303 name: RLD2302 name: RLD2102 measure: AUCt measure: Cmax measure: AUCinf measure: Tmax measure: t1/2 measure: CL/F measure: Vd/F sex: ALL minimumAge: 19 Years maximumAge: 54 Years stdAges: ADULT facility: Jeonbuk University Hospital city: Jeonju state: Jeollabuk-do country: Korea, Republic of name: Jin A Lee, Researcher role: CONTACT phone: 063-259-3550 name: Min-gul Kim, MD role: PRINCIPAL_INVESTIGATOR lat: 35.82194 lon: 127.14889 hasResults: False
nctId: NCT06357897 id: 0093/67 briefTitle: The Efficacy and Palatability of Developed Polyethylene Glycol-based Formula for Children With Functional Constipation overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-05 date: 2026-06 date: 2024-04-10 date: 2024-04-12 name: Chulalongkorn University class: OTHER briefSummary: This study aims to evaluate the efficacy and palatability of a developed polyethylene glycol-based formula compared with the standard polyethylene glycol (PEG) in the treatment of children with functional constipation for 8 weeks. Besides, we also aim to assess the side effects of a developed PEG-based formula as well as evaluate the change of rectal diameter from baseline at each visit between 2 groups. conditions: Functional Constipation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Intervention group received PEG-Chula Control group received Forlax primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: The intervention and control were prepared in the similar sachet and was blinded to investigatiors, participants and guardians whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 52 type: ESTIMATED name: Local PEG4000 name: Commercial PEG4000 measure: The frequency of stool measure: Stool consistency assessed by Bristol stool chart measure: Fecal incontinence measure: Rectal diameter measure: Adverse events measure: Palatability of medication assessed by facial Hedonic scale sex: ALL minimumAge: 6 Months maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Faculty of Medicine, Chulalongkorn University city: Bangkok zip: 10330 country: Thailand lat: 13.75398 lon: 100.50144 hasResults: False
nctId: NCT06357884 id: CREC2023.572 briefTitle: Short-term Effect of Podiatric Callus Debridement on Plantar Pressure in Diabetic Neuropathic Patients overallStatus: RECRUITING date: 2024-02-23 date: 2024-04-20 date: 2024-04-30 date: 2024-04-10 date: 2024-04-10 name: Chinese University of Hong Kong class: OTHER name: Princess Margaret Hospital, Hong Kong briefSummary: Diabetes peripheral neuropathy (DPN) affects up to 50% of the diabetes population. In the diabetic neuropathic foot, it commonly manifests as loss of protective sensation, foot deformity and skin dryness. Alongside with day-to-day weightbearing activities, this can lead to formation of callus over plantar pressure points. Studies have proven that callus formation leads to high plantar pressure and increased risk of diabetic foot ulcers. For podiatrists, diabetic foot screening and treatment is our daily practice. Plantar callus are commonly treated by sharp debridement to relief pressure from the hard skin build up and thus reducing the risk of ulceration. However, the effectiveness of callus sharp debridement is not commonly studied in researches. Only a few studies in the past evaluated the effectiveness of callus treatment by different outcome measurements. Among those studies only 2 were specifically done in diabetic patients, in which one reported results of diabetic neuropathic patients. All the available studies used peak plantar pressure only as their pedobarographic outcome measure. In this study, the treatment effect of podiatric sharp debridement of callus in diabetic neuropathic patients will be evaluated using a range of pedobarographic parameters and Foot and Ankle Outcome Score (FAOS) questionnaire. The immediate and short-term (3-4 weeks) effect of sharp debridement in DPN patients with callus could be quantified. Change in loading pattern could also be analysed based on different areas of the foot. conditions: Diabetic Neuropathies conditions: Plantar Callus studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 16 type: ESTIMATED name: Callus debridement measure: Peak plantar pressure (PPP) (unit: kPa) measure: Pressure time integral (PTI) (unit: kPa*sec) measure: Peak pressure gradient (PPG) (unit: kPa/cm) measure: Forefoot to rearfoot peak pressure ratio (F/R ratio) measure: Foot and Ankle Outcome Score (FAOS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Podiatry Department, Princess Margaret Hospital status: RECRUITING city: Hong Kong country: Hong Kong name: Joanne Tze Yan Lai role: CONTACT phone: 29903901 lat: 22.27832 lon: 114.17469 hasResults: False
nctId: NCT06357871 id: 2023PI178 briefTitle: Role of Renal Biopsy in the Suspicion of Nephrotoxicity of Immunotherapy (Checkpoint Inhibitors) in Solid Cancer acronym: NEPHROTOX overallStatus: RECRUITING date: 2023-11-28 date: 2025-12-31 date: 2025-12-31 date: 2024-04-10 date: 2024-04-10 name: Central Hospital, Nancy, France class: OTHER name: University Hospital, Strasbourg, France name: CHU de Reims name: Centre Hospitalier Régional Metz-Thionville name: European Georges Pompidou Hospital briefSummary: Checkpoint inhibitors represent a new class of widely used immunotherapy, however with immune-mediated adverse effects, with renal damage estimated at 1.4% and 4.9% depending on the series.
We aim to establish a probability score for the presence of histological NTIA lesions in a patient treated with CPI who presents with acute renal failure in order to guide the nephrologist and oncologist in their management in the event of AKI at the CPI, and determine the usefulness of a PBR to guide the suspension/resumption of immunotherapy +/- associated corticosteroid therapy; avoiding a PBR exposing to a high iatrogenic risk and sometimes impossible. conditions: Chemotherapeutic Toxicity studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 100 type: ESTIMATED name: No intervention measure: Estimation using a multivariate model of the factors associated with the histological presence of NTIA vs NTA lesions in a patient treated with CPI sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHRU de Nancy status: RECRUITING city: Vandoeuvre les nancy zip: 54500 country: France name: Adrien Flahault, MD PhD role: CONTACT phone: 0383858585 email: a.flahault@chru-nancy.fr lat: 48.65 lon: 6.18333 hasResults: False
nctId: NCT06357858 id: CASE6323 briefTitle: ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-02-28 date: 2026-02-28 date: 2024-04-10 date: 2024-04-10 name: Case Comprehensive Cancer Center class: OTHER briefSummary: The goal of this clinical trial is to see if the combination of experimental drug ASTX727 and Nivolumab enhances the antitumor immune response in participants will recurrent or metastatic squamous cell carcinoma of the head and neck.
Participants will take a pill called ASTX727 for 4 or 5 days every month followed by an injection of Nivolumab one week after the first dose of study medication. conditions: Recurrent Squamous Cell Carcinoma of the Head and Neck conditions: Metastatic Squamous Cell Carcinoma conditions: Head and Neck Squamous Cell Carcinoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 15 type: ESTIMATED name: INQOVI (decitabine and cedazuridine) name: Nivolumab measure: Pharmacodynamics Effect of ASTX727 on global DNA methylation status measure: Immunogenicity of ASTX27 in combination with Nivolumab measure: Maximum Tolerated Dose measure: Safety of ASTX measure: Objective Response Rate (ORR) measure: Overall Survival (OS) sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center city: Cleveland state: Ohio zip: 44106 country: United States name: Kyunghee Burkitt, DO, PhD role: CONTACT phone: 216-844-0512 email: Kyunghee.Burkitt@UHhospitals.org lat: 41.4995 lon: -81.69541 hasResults: False
nctId: NCT06357845 id: CASE5Z24 id: 1R21ES036031-01 type: NIH link: https://reporter.nih.gov/quickSearch/1R21ES036031-01 briefTitle: Linking Somatic Mutation Rate With Baseline Exposure in East Palestine overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-09-01 date: 2026-01-31 date: 2024-04-10 date: 2024-04-10 name: Case Comprehensive Cancer Center class: OTHER name: National Institutes of Health (NIH) name: National Institute of Environmental Health Sciences (NIEHS) briefSummary: The goal of this study is to This research team is conducting this study to develop methods to measure the biological impact of exposure to the chemicals released following the February 3, 2023 train derailment on residents of East Palestine, Ohio, and surrounding communities. The main question it aims to answer is:
* A total of 40 study participants will be recruited to participate in a 90-minute interview. The interviews will be video and audio recorded. conditions: Somatic Mutation studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: A cross-sectional study design will be implemented. primaryPurpose: SCREENING masking: NONE count: 500 type: ESTIMATED name: Survey name: Biological specimen collection name: Communications about study updates and future research opportunities name: Qualitative interview measure: Geographic Association of Somatic Mutation Rates measure: Self-reported Symptomology Association of Somatic Mutation Rates sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06357832 id: CTP-ACCiTBS-00 briefTitle: New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD) overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2024-10-15 date: 2024-12-15 date: 2024-04-10 date: 2024-04-12 name: Brainsway class: INDUSTRY briefSummary: The BrainsWay Deep Transcranial Magnetic Stimulation (Depp TMS) device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep brain TMS by means of repetitive pulse trains at a determined frequency. The purpose of the current study is to evaluate the safety and effectiveness of a new investigational stimulation protocol delivered with the BrainsWay Deep TMS device, for the treatment of MDD, demonstrating that it is non-inferior to the current standard-of-care stimulation protocol, in a randomized, controlled study. conditions: Major Depressive Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 104 type: ESTIMATED name: Brainsway Deep TMS System measure: Change in Hamilton Depression Rating Scale (HDRS)-21 score in the investigational group measure: Response rate in the investigational group measure: Remission rate in the investigational group measure: Change in Clinical Global Impression-Severity (CGI-S) scores in the investigational group measure: Change in Clinical Global Impression Improvement (CGI-I) scores in the investigational group sex: ALL minimumAge: 22 Years maximumAge: 68 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Novus Neurology city: Tuscaloosa state: Alabama zip: 35401 country: United States name: Timothy Prestley, MD role: CONTACT phone: 205-523-5618 email: timprestley@gmail.com lat: 33.20984 lon: -87.56917 facility: DTMS Center LLC city: Palm Beach state: Florida zip: 33401 country: United States name: Aron Tendler, MD role: CONTACT phone: 561-749-9999 email: aron.tendler@gmail.com lat: 26.70562 lon: -80.03643 facility: Fermata Health city: Brooklyn state: New York zip: 11249 country: United States name: Owen Muir, MD role: CONTACT phone: 929-346-4317 email: owen@fermata.health lat: 40.6501 lon: -73.94958 facility: Complete Mind Care of PA city: Abington state: Pennsylvania zip: 19001 country: United States name: Samson Seplow, MD role: CONTACT phone: 215-254-6000 email: Dr.Seplow@cmcofpa.com lat: 40.12067 lon: -75.11795 facility: ClearPath Psychiatry city: Seattle state: Washington zip: 98105 country: United States name: Molly Davis, MD role: CONTACT phone: 206-486-8150 email: mollydavis@clearpathpsychiatry.com lat: 47.60621 lon: -122.33207 facility: PsyCare city: South Charleston state: West Virginia zip: 25303 country: United States lat: 38.36843 lon: -81.69957 hasResults: False
nctId: NCT06357819 id: CLS-017A id: HSTAR010 type: OTHER domain: HSTAR Programme id: EZIMOM012 type: OTHER domain: Ezintsha briefTitle: INSTI® HCV (Hepatitis C Virus) Antibody Self-Test Contrived Result Interpretation overallStatus: COMPLETED date: 2023-10-12 date: 2023-12-17 date: 2023-12-17 date: 2024-04-10 date: 2024-04-10 name: bioLytical Laboratories class: INDUSTRY briefSummary: The purpose of this Interpretation Assessment was to document if "lay" people, non-professional and inexperienced in self-testing, were able to successfully perform the steps to use a Hepatitis C Virus (HCV) Self-Test (HCVST) device, without product familiarization \[demonstration\]. conditions: Hepatitis C studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 405 type: ACTUAL name: INSTI HCV Self Test measure: Successful Interpretation of contrived devices sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: bioLytical Laboratories Inc. city: Richmond state: British Columbia zip: V6V 2A2 country: Canada lat: 49.17003 lon: -123.13683 hasResults: False
nctId: NCT06357806 id: PIN-CHB-1 briefTitle: The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-09-30 date: 2025-09-30 date: 2024-04-10 date: 2024-04-10 name: Beijing 302 Hospital class: OTHER briefSummary: This is a prospective, open-labled, randomized controlled study to assess efficacy and safety of treatment with Sintilimab (PDL-1 antibody) combined Peg-IFNα-2b in CHB patients on stable NAs treatment. conditions: Chronic Hepatitis B studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 45 type: ESTIMATED name: Sintilimab name: Peg-IFNα-2b name: NAs measure: The rate of HBsAg loss at 24 weeks and 48 weeks. measure: Incidence of treatment-emergent adverse events/serious adverse events measure: The rate of HBsAg decline > 1log(IU/ml) at 24 weeks and 48 weeks measure: The rate of HBsAb positive at 24 weeks and 48 weeks. measure: The concentration of HBcrAg at baseline, 12 weeks, 24 weeks and 48 weeks. measure: The concentration of pgRNA at baseline, 12 weeks, 24 weeks and 48 weeks. measure: The concentration of anti-HBc at baseline, 12 weeks, 24 weeks and 48 weeks. measure: Immune response of T cell, B cell, NK cell at baseline, 12 weeks, 24 weeks and 48 weeks. sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: the Fifth Medical Center, Chinese PLA General Hospital city: Beijing state: Beijing zip: 100039 country: China name: Junliang Fu, MD role: CONTACT phone: 010-66933214 email: fjunliang@163.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06357793 id: camsakuraftr briefTitle: Evaluation of Work Productivity and Activities of the Fibromyalgia Patients' Relatives overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2024-11-15 date: 2024-12-15 date: 2024-04-10 date: 2024-04-18 name: Başakşehir Çam & Sakura City Hospital class: OTHER_GOV briefSummary: Patients suffering from fibromyalgia (FM) are challenged by symptoms such as chronic pain, fatigue, sleep disturbance and emotional distress. Patients diagnosed with fibromyalgia can also negatively affect the relatives they live with due to their existing complaints. It is possible that their relatives accompanying them may lose their workforce due to untreated pain complaints and frequent hospital admissions. The main purpose of our study is to examine whether there is any impact on the working life of the people they live with and whether there is a decrease in their work productivity. conditions: Fibromyalgia conditions: Work Productivity conditions: Quality of Life conditions: Pain, Chronic studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 122 type: ESTIMATED measure: Work Productivity and Activity of Fibromyalgia Patients' Relatives measure: Quality of life Fibromyalgia Patients' Relatives sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06357767 id: S06GM146079 type: NIH link: https://reporter.nih.gov/quickSearch/S06GM146079 briefTitle: Smoking Cessation Intervention for American Indian Women Experiencing Intimate Partner Violence overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-07-31 date: 2026-01-31 date: 2024-04-10 date: 2024-04-22 name: Black Hills Center for American Indian Health class: OTHER name: Yale University briefSummary: The goal of this project is to refine and test a culturally-tailored smoking cessation intervention for American Indian women who have experienced intimate partner violence (IPV). The primary aims of this study are to: (a) use a community-based participatory approach to refine intervention materials and finalize pilot intervention methodology for a culturally tailored, trauma-informed smoking cessation intervention for AI women who have experienced IPV; (b) examine feasibility, acceptability, satisfaction, and preliminary efficacy of the intervention; and (c) explore changes in alcohol and drug use over the course of the intervention.